Literature DB >> 12769525

Antimutagenicity of supercritical CO2 extracts of Terminalia catappa leaves and cytotoxicity of the extracts to human hepatoma cells.

Ting-Fu Ko1, Yih-Ming Weng, Shwu-Bin Lin, Robin Y-Y Chiou.   

Abstract

Natural antimutagens may prevent cancer and are therefore of great interest to oncologists and the public at large. Phytochemicals are potent antimutagen candidates. When the Ames test was applied to examine the antimutagenic potency of supercritical carbon dioxide (SC-CO(2)) extracts of Terminalia catappa leaves at a dose of 0.5 mg/plate, toxicity and mutagenicity were not detected. The antimutagenic activity of SC-CO(2) extracts increased with decreases of temperature (60, 50, and 40 degrees C) and pressure (4000, 3000, and 2000 psi) used for extraction. The most potent antimutagenicity was observed in extracts obtained at 40 degrees C and 2000 psi. At a dose of 0.5 mg of extract/plate, approximately 80% of the mutagenicity of benzo[a]pyrene (B[a]P, with S-9) and 46% of the mutagenicity of N-methyl-N '-nitroguanidine (MNNG, without S-9) were inhibited. Media supplemented with SC-CO(2) extracts at a range of 0-500 microg/mL were used to cultivate human hepatoma (Huh 7) and normal liver (Chang liver) cells. The viability of the cells was assayed by measuring cellular acid phosphatase activity. A dose-dependent growth inhibition of both types of cells was observed. The SC-CO(2) extracts were more cytotoxic to Huh 7 cells than to Chang liver cells. The observation that SC-CO(2) extracts of T. catappa leaves did not induce mutagenicity at the doses tested while exhibiting potent antimutagenicity and were more cytotoxic to human hepatoma cells than to normal liver cells is of merit and warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12769525     DOI: 10.1021/jf034102v

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.279


  7 in total

Review 1.  Oxidative stress--implications, source and its prevention.

Authors:  Rajbir Kaur; Jasmit Kaur; Jyoti Mahajan; Rakesh Kumar; Saroj Arora
Journal:  Environ Sci Pollut Res Int       Date:  2013-10-30       Impact factor: 4.223

Review 2.  An updated review of Terminalia catappa.

Authors:  Arumugam Vijaya Anand; Natarajan Divya; Pannerselvam Punniya Kotti
Journal:  Pharmacogn Rev       Date:  2015 Jul-Dec

3.  Terminalia catappa Exerts Antimetastatic Effects on Hepatocellular Carcinoma through Transcriptional Inhibition of Matrix Metalloproteinase-9 by Modulating NF-κB and AP-1 Activity.

Authors:  Chao-Bin Yeh; Ming-Ju Hsieh; Yih-Shou Hsieh; Ming-Hsien Chien; Pen-Yuan Lin; Hui-Ling Chiou; Shun-Fa Yang
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-08       Impact factor: 2.629

4.  Effect of Terminalia catappa on lipid profile in transplanted fibrosarcoma in rats.

Authors:  Pandya Naitik; Tigari Prakash; Dupadahalli Kotresha; Nadendla Rama Rao
Journal:  Indian J Pharmacol       Date:  2012-05       Impact factor: 1.200

5.  Terminalia Catappa Extract (TCE) Reduces Proliferation of Lung and Breast Cancer Cell by Modulating miR-21 and miR-34a Expressions.

Authors:  Habib Zarredar; Amir Mahdi Khamaneh; Fatemeh Firouzi Amoodizaj; Dariush Shanaehbandi; Ensiyeh Seyedrezazadeh; Hamed Sabagh Jadid; Milad Asadi; Venus Zafari; Yeganeh Khalili; Zahra Soleimani; Atefeh Ansarin; Majid Khalili
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01

6.  Characterization and Quantification of Compounds in the Hydroalcoholic Extract of the Leaves from Terminalia catappa Linn. (Combretaceae) and Their Mutagenic Activity.

Authors:  Francisco José Mininel; Carlos Sérgio Leonardo Junior; Lívia Greghi Espanha; Flávia Aparecida Resende; Eliana Aparecida Varanda; Clarice Queico Fujimura Leite; Wagner Vilegas; Lourdes Campaner Dos Santos
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-09       Impact factor: 2.629

7.  Terminalia catappa attenuates urokinase-type plasminogen activator expression through Erk pathways in Hepatocellular carcinoma.

Authors:  Chao-Bin Yeh; Yung-Luen Yu; Chiao-Wen Lin; Hui-Ling Chiou; Ming-Ju Hsieh; Shun-Fa Yang
Journal:  BMC Complement Altern Med       Date:  2014-04-30       Impact factor: 3.659

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.